NASDAQ · Biotechnology

Midatech Pharma plc (MTP) Stock

$0.29 -18.50% NASDAQ: MTP Healthcare

Midatech Pharma plc is a pharmaceutical company focused on the research and development of drug delivery technologies and therapeutic solutions across the United Kingdom, Europe, and international markets. Its active pipeline includes MTX110, an investigational direct-delivery treatment for aggressive brain tumors such as diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.

Valuation

MetricValue
Price$0.29
Market Cap$1.98M
P/E Ratio-0.02
P/B Ratio158.74
P/S Ratio0.00
EPS (TTM)$-11.57
52-Week High$20.80
52-Week Low$0.19
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-88.14%
ROA-38.76%
ROCE-94.39%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.09
Current Ratio1.75

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$1.0M$1.0M$0$0
Operating Profit$-11.0M$-7.0M$-9.0M$-8.0M$-9.0M
Net Profit$-22.0M$-5.0M$-8.0M$-7.0M$-6.0M
EPS$-143.27$-35.25$-49.43$-2.29$-11.57
Op Margin-3111.1%-1210.7%-1277.8%-2103.4%—

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$10.0M$13.0M$6.0M$11.0M$15.0M
Total Liabilities$3.0M$2.0M$2.0M$6.0M$6.0M
Cash$8.0M$10.0M$3.0M$6.0M$2.0M
Borrowings$0$1.0M$1.0M$0$1.0M

Latest News

M6 Group Wins the Award for Best General Meeting Brochure at the 2026 Transparency Awards Business Wire · Jul 3, 2026 Metaplanet Adds 2,823 Bitcoin in Q2 as Buying Pace Cools decrypt · Jul 2, 2026 M6 Metropole Television: Separation of the "Stéphane Plaza Immobilier" and "Sixieme Avenue, l'immobilier par M6" Networks Business Wire · Jul 2, 2026 South Korea’s New Rules Put Crypto Treasury Firms at Risk of Major Delisting BeInCrypto · Jun 29, 2026 Motorpoint Group PLC (LSE:MOTR) Full Year 2026 Earnings Call Highlights: Record Sales and ... GuruFocus.com · Jun 17, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-9.0M$-6.0M$-7.0M$-7.0M$-12.0M
Investing Cash Flow$2.0M$-1.0M$0$-1.0M$-1.0M
Financing Cash Flow$0$0$0$0$9.0M
Net Cash Flow$-3.0M$3.0M$-7.0M$3.0M$-4.0M
Free Cash Flow$-10.0M$-6.0M$-7.0M$-7.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.06
FCF Yield-881.59%
Quick Ratio1.75
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Midatech Pharma plc

Midatech Pharma plc is a pharmaceutical company focused on the research and development of drug delivery technologies and therapeutic solutions across the United Kingdom, Europe, and international markets. Its active pipeline includes MTX110, an investigational direct-delivery treatment for aggressive brain tumors such as diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. Also in development are MTX114, a topical immunosuppressant for managing psoriasis; MTD211, an extended-release formulation of brexpiprazole for schizophrenia and as an adjunct for major depressive disorder; and MTD219, a long-acting version of tacrolimus designed to mitigate the risk of organ transplant rejection. The company also leverages proprietary drug delivery platforms: Q-Sphera, a polymer microsphere microtechnology for sustained drug release; MidaSolve, an oligosaccharide nanotechnology enabling the solubilization and direct, localized liquid administration of drugs into tumors; and MidaCore, a gold nanoparticle system engineered for targeted delivery of chemotherapeutic or immunotherapeutic agents to disease sites. Founded in 2000, Midatech Pharma plc is headquartered in Cardiff, United Kingdom.

Midatech Pharma plc is headquartered in GB.

Midatech Pharma plc (MTP) stock trades at $0.29 with a market capitalization of $1.98M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 158.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.19 and $20.80, and currently trades 98.6% below its 52-week high.

On profitability, Midatech Pharma plc generates a return on equity (ROE) of -88.14%, return on capital employed of -94.39%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.midatechpharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides